Brief Review of Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel— Bar-On 2021

This is a brief audio review. In the article Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel published, 2021 by Bar-On and Colleagues, The outcomes and key points are as noted: COVID-19 and severe illness were lower amongst patients who received a third/booster dose of BNT162B2 in patients 60 year young or older. Adjusted rate ratio 11.3 (95% confidence interval, 10.4 to 12.3) comparing individuals who did not receive a booster to those who did receive a booster with respect to developing confirmed COVID 19 infection. Adjusted rate ratio 19.5 (95% confidence interval, 12.9 to 29.5) comparing individuals who did not receive a booster to those who did receive a booster with respect to developing severe COVID 19 infection. In a Prospective Cohort Observational study with 1137804 Patients who were 60 years of age or older and who had been fully vaccinated before March 1, 2021, had available data regarding sex, had no documented positive result on polymerase-chain-reaction assay for SARS-CoV-2 before July 30, 2021, and had not returned from travel abroad in August 2021.

Gordon AC, Angus DC, Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply. N Engl J Med. 2021 Sep 16;385(12):1147-1149. doi: 10.1056/NEJMc2108482. Epub 2021 Aug 18. PMID: 34407335.